Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

By Fineline Cube #Auto-immune #HKG: 2509 #Market approval filings

Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China’s National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.

Regulatory Milestone

ItemDetail
AgencyNational Medical Products Administration (NMPA)
Filing TypeNew Drug Application (NDA)
Acceptance NumberCXSS2600039
ProductQX002N
Drug ClassHigh-affinity monoclonal antibody targeting IL-17A
IndicationActive ankylosing spondylitis (AS) in adults
DeveloperQyuns Therapeutics (HKG: 2509)
MilestoneFirst innovative drug NDA for Qyuns
Acceptance Date10 Mar 2026

Drug Profile & Mechanism

AttributeQX002N Specification
TargetInterleukin-17A (IL-17A) – including both IL-17AA and IL-17AF homodimers/heterodimers
Binding AffinityHigh-affinity monoclonal antibody
MechanismBlocks IL-17A interaction with IL-17 receptor → inhibits pro-inflammatory cytokine release
Pathophysiological Role• Induces pro-inflammatory cytokines
• Regulates bone metabolism
• Primary driver of AS pathogenesis (enthesitis, bone erosion, new bone formation)
Clinical OutcomeSlows disease progression; reduces spinal inflammation and structural damage

Market Context & Competitive Landscape

FactorMarket Implication
China AS Prevalence~5 million patients; underdiagnosis common; biologic penetration <10% vs. 30%+ in Western markets
Standard of Care EvolutionNSAIDs → TNF inhibitors (adalimumab) → IL-17A inhibitors (secukinumab, ixekizumab) as second-line
IL-17A Class ValidationSecukinumab (Novartis) and ixekizumab (Eli Lilly) established efficacy in AS; QX002N follows validated mechanism
Qyuns PositioningDomestic innovator with potential cost advantage vs. multinational originators
Pricing PressureNRDL negotiation anticipated; biosimilar competition emerging for reference products

Competitive Dynamics

CompetitorProductMechanismChina StatusQX002N Differentiation
NovartisCosentyx (secukinumab)IL-17A inhibitorApproved (AS)First-to-class; established market presence
Eli LillyTaltz (ixekizumab)IL-17A inhibitorApproved (AS)Strong efficacy data; pediatric expansion
AbbVieHumira (adalimumab)TNF inhibitorApproved (AS); biosimilars availableEarlier line positioning; IL-17A for TNF failures
QyunsQX002NIL-17A inhibitorNDA acceptedChina-developed; potential manufacturing cost advantage; local commercial infrastructure

Development Outlook

PhaseTimelineObjectives
NDA Review2026-2027NMPA technical review; clinical site inspection; manufacturing audit
ApprovalQ4 2026 – Q1 2027Conditional or full approval anticipated
Commercial Launch2027Hospital formulary access; rheumatologist education; patient identification
NRDL Negotiation2027-2028National reimbursement list inclusion critical for volume expansion
Pipeline ExpansionOngoingPsoriasis, psoriatic arthritis potential indications

Forward‑Looking Statements
This brief contains forward‑looking statements regarding NDA review timelines, regulatory approval, and commercial positioning for QX002N. Actual results may differ due to NMPA review delays, competitive dynamics with established IL-17A inhibitors, and pricing negotiations.-Fineline Info & Tech

Related Post

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube
Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Fineline Cube

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market